We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Concordia Diversifies Portfolio With $3.5 Billion Amdipharm Acquisition
The item has been added to your shopping cart.
Concordia Diversifies Portfolio With $3.5 Billion Amdipharm Acquisition
Concordia Healthcare is acquiring UK-based Amdipharm Mercury for $3.5 billion, in a deal that greatly expands the Canadian drugmaker’s generic portfolio and global reach.